Sigma Investment Counselors Inc. bought a new position in Align Technology, Inc. (NASDAQ:ALGN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,150 shares of the medical equipment provider’s stock, valued at approximately $214,000.

A number of other hedge funds have also recently modified their holdings of ALGN. Crossmark Global Holdings Inc. purchased a new position in shares of Align Technology during the 3rd quarter valued at about $2,875,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Align Technology during the 2nd quarter valued at about $1,768,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Align Technology during the 2nd quarter valued at about $454,000. American Century Companies Inc. grew its position in shares of Align Technology by 2,236.0% during the 2nd quarter. American Century Companies Inc. now owns 221,009 shares of the medical equipment provider’s stock valued at $33,178,000 after acquiring an additional 211,548 shares during the period. Finally, Robeco Institutional Asset Management B.V. grew its position in shares of Align Technology by 17.8% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 90,969 shares of the medical equipment provider’s stock valued at $13,657,000 after acquiring an additional 13,753 shares during the period. Institutional investors own 80.86% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Sigma Investment Counselors Inc. Takes Position in Align Technology, Inc. (ALGN)” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/sigma-investment-counselors-inc-takes-position-in-align-technology-inc-algn/1702776.html.

In other news, Director Greg J. Santora sold 7,700 shares of Align Technology stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $238.95, for a total transaction of $1,839,915.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CMO Raphael Pascaud sold 5,400 shares of Align Technology stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $241.88, for a total transaction of $1,306,152.00. Following the sale, the chief marketing officer now directly owns 22,228 shares in the company, valued at approximately $5,376,508.64. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Align Technology, Inc. (NASDAQ:ALGN) traded up $4.27 during mid-day trading on Tuesday, reaching $253.73. The company had a trading volume of 952,400 shares, compared to its average volume of 1,005,870. Align Technology, Inc. has a 12 month low of $88.56 and a 12 month high of $257.60. The firm has a market cap of $20,430.00, a PE ratio of 73.81, a price-to-earnings-growth ratio of 2.39 and a beta of 1.41.

Align Technology (NASDAQ:ALGN) last released its earnings results on Thursday, October 26th. The medical equipment provider reported $1.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.19. Align Technology had a net margin of 19.98% and a return on equity of 25.60%. The business had revenue of $385.30 million for the quarter, compared to analyst estimates of $359.80 million. During the same period last year, the company posted $0.63 EPS. The business’s revenue was up 38.3% on a year-over-year basis. equities research analysts expect that Align Technology, Inc. will post 3.62 EPS for the current year.

A number of equities research analysts have recently commented on the company. Stifel Nicolaus restated a “buy” rating and set a $225.00 target price (up from $205.00) on shares of Align Technology in a research report on Thursday, October 19th. Northcoast Research restated a “buy” rating and set a $230.00 target price (up from $200.00) on shares of Align Technology in a research report on Tuesday, October 10th. Credit Suisse Group restated a “positive” rating and set a $261.00 target price (up from $209.00) on shares of Align Technology in a research report on Thursday, November 9th. Bank of America Corporation upgraded Align Technology from a “neutral” rating to a “buy” rating and raised their target price for the company from $175.00 to $193.00 in a research report on Friday, July 28th. Finally, Zacks Investment Research upgraded Align Technology from a “hold” rating to a “buy” rating and set a $227.00 target price on the stock in a research report on Monday, October 30th. Eleven analysts have rated the stock with a buy rating, Align Technology has an average rating of “Buy” and a consensus price target of $219.18.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Institutional Ownership by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.